Fusen Pharmaceutical Company Limited

1652

KYG370981030

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:25 30/05/2024 pm IST			5-day change	1st Jan Change
1.2 ^HKD	0.00%		+1.69%	-12.41%

04/04	Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	MT
03/04	Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)	CI

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

August 29, 2022 at 07:13 pm IST

The directors of Fusen Pharmaceutical Company Limited do not recommend the payment of a dividend in respect of the six months ended 30 June 2022 (six months ended 30 June 2021: RMB 0.57 cents).

Latest news about Fusen Pharmaceutical Company Limited

Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	04/04	MT
Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)	03/04	CI
Fusen Pharmaceutical Posts Higher Loss in 2023	01/04	MT
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	15/03	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Fusen Pharmaceutical Forecasts Return to Profitability in H1	11/23/11	MT
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023	10/23/10	CI
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 75,843,900 shares, representing 10% of its issued share capital, under the authorization approved on May 30, 2023.	31/23/31	CI
Fusen Pharmaceutical Company Limited's Equity Buyback announced on June 2, 2022, has expired.	30/23/30	CI
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	28/23/28	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Year Ended 31 December 2022	28/23/28	CI
Fusen Pharmaceutical to Swing to Loss in 2022	14/23/14	MT
Fusen Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ended 31 December 2022	13/23/13	CI
Fusen Pharmaceutical, Directors Hit with Disciplinary Action for Disclosure Breaches	04/23/04	MT
Fusen Pharmaceutical Company Limited Announces Change of Principal Place of Business in Hong Kong	15/22/15	CI
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	29/22/29	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022	29/22/29	CI
Fusen Pharmaceutical Forecasts Swing to Loss in January-June Results	22/22/22	MT
Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022	19/22/19	CI
Fusen Pharmaceutical Company Limited, as Distributor, and Taumedika Srl., an Independent Third Party, as Supplier, Entered into Distribution Agreement	18/22/18	CI
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 76,993,400 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2022.	02/22/02	CI
Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021	31/22/31	CI

Chart Fusen Pharmaceutical Company Limited

Duration

Period

Chart Fusen Pharmaceutical Company Limited

More charts

Fusen Pharmaceutical Co Ltd is a China-based company principally engaged in the provision of Shuanghuanglian series cold medicines. The Company is mainly engaged in research, development, production and sales of Chinese patent drugs and western medicine products for the treatment of cold and fever, cardiovascular diseases and anemia. The Company's main products include small volume injections, oral liquids, tablets, capsules and granules. The Company distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
FUSEN PHARMACEUTICAL COMPANY LIMITED	-12.41%	114M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.85%	42.57B
OTSUKA HOLDINGS CO., LTD.	+18.28%	21.01B
SANDOZ GROUP AG	+16.63%	14.86B
CIPLA LIMITED	+17.68%	14.47B
ZYDUS LIFESCIENCES LIMITED	+48.57%	12.61B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.56%	6.57B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.62B
GEDEON RICHTER	+6.11%	4.66B